All Stories

  1. High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment
  2. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
  3. Comparing Treatment Approaches for Older Adults with Treatment-Resistant Depression -- The OPTIMUM Study
  4. Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based population
  5. Fatness, fitness and the aging brain: A cross sectional study of the associations between a physiological estimate of brain age and physical fitness, activity, sleep, and body composition
  6. Using Implementation Science to Guide the Process of Adapting a Patient Engagement Intervention for Inpatient Spinal Cord Injury/Disorder Rehabilitation
  7. Mindfulness Training for Depressed Older Adults Using Smartphone Technology: Protocol for a Fully Remote Precision Clinical Trial
  8. Optimized, personalized, and digitalized: protocol for a fully-remote precision clinical trial of mindfulness training for depressed older adults using smartphone technology (Preprint)
  9. Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
  10. Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
  11. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
  12. Perioperative Mental Health in Older Adults: New Research on Epidemiology and Outcomes
  13. Smartphone-Based Ecological Momentary Assessment as the New Standard Measure for Post-Stroke Functioning (Preprint)
  14. Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial
  15. Comparing stress prediction models using smartwatch physiological signals and participant self-reports
  16. Effect of electroencephalogram-guided anaesthesia administration on 1-yr mortality: follow-up of a randomised clinical trial
  17. Ketamine for Depression in Older Adults
  18. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial
  19. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
  20. Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study
  21. Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen
  22. Surgical Complications in Older Adults Predict Decline in Self-Perceived Cognitive Function in the Ensuing Year: A Cohort Study
  23. Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time
  24. Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study
  25. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
  26. Executive Function Moderates Functional Outcomes of Engagement Strategies During Rehabilitation in Older Adults
  27. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
  28. COVID-19 Clinical Trials: A Voice From the Front Lines
  29. Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy
  30. Going remote: Implementing digital research methods at an academic medical center during COVID-19
  31. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders
  32. Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression
  33. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
  34. Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation
  35. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment
  36. iTBS to Relieve Depression and Executive Dysfunction in Older Adults: An Open Label Study
  37. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
  38. The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults
  39. A Qualitative Study of Perioperative Depression and Anxiety in Older Adults
  40. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders
  41. Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: A systematic review and meta-analysis
  42. Pharmacological Treatments for Tinnitus—Reply
  43. Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study
  44. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults
  45. Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials
  46. Positive information facilitates response inhibition in older adults only when emotion is task-relevant
  47. Older molecular brain age in severe mental illness
  48. Stereoselective Steady‐State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults
  49. Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample
  50. Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  51. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial
  52. Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions
  53. Preoperative Cognitive Abnormality, Intraoperative Electroencephalogram Suppression, and Postoperative Delirium
  54. Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine
  55. Central-positive complexes in ECT-induced seizures: Evidence for thalamocortical mechanisms
  56. Mood Disorders and Dementia: Time for Action
  57. mHealth Assessment and Intervention of Depression and Anxiety in Older Adults
  58. “What Were You Before the War?” Repurposing Psychiatry During the COVID-19 Pandemic
  59. Action at a Distance: Geriatric Research during a Pandemic
  60. Precision Medicine in Clinical Trials
  61. Does patient expectancy account for the cognitive and clinical benefits of mindfulness training in older adults?
  62. Tinnitus
  63. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment (Preprint)
  64. Activity Level and Intensity of Older Adults in Skilled Nursing Rehabilitation Measured via Actigraphy
  65. Neuroticism predicts fear of falling after hip fracture
  66. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  67. Predicting Remission in Late-Life Major Depression
  68. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis
  69. A qualitative study of older adults’ perspectives on initiating exercise and mindfulness practice
  70. Comorbid anxiety in late‐life depression: Relationship with remission and suicidal ideation on venlafaxine treatment
  71. Cognitive Training for Optimizing Perioperative Brain Health
  72. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized
  73. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study
  74. Obsessions are strongly related to eating disorder symptoms in anorexia nervosa and atypical anorexia nervosa
  75. Effect of Enhanced Medical Rehabilitation on Functional Recovery in Older Adults Receiving Skilled Nursing Care After Acute Rehabilitation
  76. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole
  77. Antidepressant Treatment for Late‐Life Depression: Considering Risks and Benefits
  78. An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression
  79. Emotional Response Inhibition Is Greater in Older Than Younger Adults
  80. Feasibility of Intensive Ecological Sampling of Tinnitus in Intervention Research
  81. When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials
  82. Pride and Prejudice in the Treatment of Depression and Anxiety in Acutely Ill Older Adults
  83. Diagnostic, clinical, and personality correlates of food anxiety during a food exposure in patients diagnosed with an eating disorder
  84. Crossover to Bilateral Repetitive Transcranial Magnetic Stimulation
  85. Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery
  86. Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial
  87. Assessment and treatment of major depression in older adults
  88. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
  89. Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  90. Cognitive Improvement in Older Adults in the Year After Hip Fracture: Implications for Brain Resilience in Advanced Aging
  91. Pharmacogenetic Guidelines and Decision Support Tools for Depression Treatment: Application to Late-Life
  92. Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation
  93. Scientific Biography of a Mid-Career Physician-Scientist: Getting by With Help From My Friends
  94. Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia
  95. Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression
  96. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial
  97. Meal and snack-time eating disorder cognitions predict eating disorder behaviors and vice versa in a treatment seeking sample: A mobile technology based ecological momentary assessment study
  98. Reduced GABAergic cortical inhibition in aging and depression
  99. Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol
  100. Ability of postoperative delirium to predict intermediate-term postoperative cognitive function in patients undergoing elective surgery at an academic medical centre: protocol for a prospective cohort study
  101. Childhood Trauma Is Associated With Poorer Cognitive Performance in Older Adults
  102. Cognitive Training for Older Adults: What Works?
  103. Integrative Geriatric Psychiatry
  104. Depression and Functional Impairment: A Pernicious Pairing in Older Adults
  105. Electroencephalography-Guided Minimisation of Anaesthetic Administration to Prevent Post-Operative Delirium: A Randomised, Pragmatic Trial
  106. The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment
  107. Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance
  108. Achieving Milestones as a Prerequisite for Proceeding With a Clinical Trial
  109. Alternative Facts? Antidepressants and Falls in Older Adults
  110. Fear of food prospectively predicts drive for thinness in an eating disorder sample recently discharged from intensive treatment
  111. Effects of Cable News Watching on Older Adults’ Physiological and Self-Reported Stress and Cognitive Function
  112. The role of depression pharmacogenetic decision support tools in shared decision making
  113. Specific depressive symptoms predict remission to aripiprazole augmentation in late‐life treatment resistant depression
  114. Mindfulness-Based Stress Reduction for Older Adults With Stress Disorders and Neurocognitive Difficulties
  115. Potentially Inappropriate Medications and the Time to Full Functional Recovery After Hip Fracture
  116. Evaluation of Ecological Momentary Assessment for Tinnitus Severity
  117. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  118. Plasma REST: a novel candidate biomarker of Alzheimer’s disease is modified by psychological intervention in an at-risk population
  119. Bone Turnover with Venlafaxine Treatment in Older Adults with Depression
  120. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults
  121. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders
  122. Predictors of Posttraumatic Stress Symptoms and Association with Fear of Falling After Hip Fracture
  123. Fear of Falling after Hip Fracture: Prevalence, Course, and Relationship with One-Year Functional Recovery
  124. Enhanced Medical Rehabilitation: Effectiveness of a clinical training model
  125. Telephone-Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial
  126. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder
  127. Consequences of Anxiety in Aging and Cognitive Decline
  128. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation
  129. Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study
  130. Gray matter regions statistically mediating the cross‐sectional association of eotaxin and set‐shifting among older adults with major depressive disorder
  131. Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression
  132. Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias.
  133. Immunological biomarkers associated with brain structure and executive function in late‐life depression: exploratory pilot study
  134. Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial
  135. Treatment Emergent Suicidal Ideation in depressed older adults
  136. Use of the Temperament and Character Inventory to Predict Response to Repetitive Transcranial Magnetic Stimulation for Major Depression
  137. Feasibility and Acceptability of Smartphone Assessment in Older Adults with Cognitive and Emotional Difficulties
  138. Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.
  139. Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults
  140. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression
  141. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial
  142. Trajectories of depressive symptoms after hip fracture
  143. Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences
  144. Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment
  145. Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial
  146. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
  147. Solving the Geriatric Mental Health Crisis in the 21st Century
  148. Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults
  149. Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review
  150. Response to Stubbs's Letter to the Editor
  151. Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment
  152. Treating Anxiety Disorders in Older Adults
  153. A new measure of fear of falling: psychometric properties of the fear of falling questionnaire revised (FFQ-R)
  154. <span style="font-variant:small-caps; ">d</span>-Cycloserine Facilitation of Exposure Therapy Improves Weight Regain in Patients With Anorexia Nervosa
  155. Clarifying the Behavioral Economics of Social Anxiety Disorder
  156. Effect of Physical Activity, Social Support, and Skills Training on Late-Life Emotional Health: A Systematic Literature Review and Implications for Public Health Research
  157. Association of Functional Polymorphisms from Brain-Derived Neurotrophic Factor and Serotonin-Related Genes with Depressive Symptoms after a Medical Stressor in Older Adults
  158. Response to Mohler and Colleagues
  159. Effects of Mindfulness Based Stress Reduction Therapy on Subjective Bother and Neural Connectivity in Chronic Tinnitus
  160. Ecological Momentary Assessment of Tinnitus Using Smartphone Technology
  161. A Novel Treatment for Tinnitus and Tinnitus-Related Cognitive Difficulties Using Computer-Based Cognitive Training and D-Cycloserine
  162. Short-term affective recovery from hip fracture prospectively predicts depression and physical functioning.
  163. Common Selective Serotonin Reuptake Inhibitor Side Effects in Older Adults Associated with Genetic Polymorphisms in the Serotonin Transporter and Receptors: Data from a Randomized Controlled Trial
  164. How bandwidth selection algorithms impact exploratory data analysis using kernel density estimation.
  165. Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
  166. Development and Testing of Treatments
  167. Planning Grants
  168. Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review
  169. Combiningd-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke
  170. Patient Active Time During Therapy Sessions in Postacute Rehabilitation: Development and Validation of a New Measure
  171. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone
  172. Mindfulness-based stress reduction for older adults with worry symptoms and co-occurring cognitive dysfunction
  173. Dynamic Prediction of Treatment Response in Late-Life Depression
  174. Is There a Role for Antidepressant and Antipsychotic Pharmacogenetics in Clinical Practice in 2014?
  175. Validation of the Ambivalent and Purposeful Engagement – Trait Measure
  176. Anxiety Disorders
  177. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults
  178. Anxiety Disorders in Older Adults: Looking to DSM5 and Beyond…
  179. Antidepressant Medication Augmented With Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
  180. Research to Reduce the Suicide Rate Among Older Adults: Methodology Roadblocks and Promising Paradigms
  181. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder
  182. Lessons Learned Fromd-Cycloserine: The Promise and Limits of Drug Facilitation of Exposure Therapy
  183. Enhanced Medical Rehabilitation Is Feasible in a Skilled Nursing Facility: Preliminary Data on a Novel Treatment for Older Adults With Depression
  184. Serotonin–norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption
  185. A HIGH-THROUGHPUT CLINICAL ASSAY FOR TESTING DRUG FACILITATION OF EXPOSURE THERAPY
  186. Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial
  187. Functional network dysfunction in anxiety and anxiety disorders
  188. Measuring Treatment Fidelity in a Rehabilitation Intervention Study
  189. Reversal of SSRI-Associated Urinary Retention With Mirtazapine Augmentation
  190. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors
  191. Comorbid anxiety and depression: bête noire or quick fix?
  192. Memantine for late‐life depression and apathy after a disabling medical event: a 12‐week, double‐blind placebo‐controlled pilot study
  193. Inflammatory Cytokine Levels and Depressive Symptoms in Older Women in the Year After Hip Fracture: Findings from the Baltimore Hip Studies
  194. Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder
  195. Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group
  196. Treatment‐related alteration of cortisol predicts change in neuropsychological function during acute treatment of late‐life anxiety disorder
  197. Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: A Placebo-Controlled Evaluation of Escitalopram
  198. Treating Depression in Older Adults with Dementia
  199. Anxiety Disorders: New Developments in Old Age
  200. Altered cerebral blood flow patterns associated with pathologic worry in the elderly
  201. Maintenance Treatment of Depression in Old Age
  202. Relation of Serotonin Transporter Genetic Variation to Efficacy of Escitalopram for Generalized Anxiety Disorder in Older Adults
  203. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study
  204. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management
  205. Anxiety disorders in older adults: a comprehensive review
  206. Cognitive and Affective Predictors of Rehabilitation Participation After Stroke
  207. Use of the Late‐Life Function and Disability Instrument to Assess Disability in Major Depression
  208. Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers
  209. fMRI activation in late‐life anxious depression: a potential biomarker
  210. Apathy After Hip Fracture: A Potential Target for Intervention to Improve Functional Outcomes
  211. The Burden of Late-Life Generalized Anxiety Disorder: Effects on Disability, Health-Related Quality of Life, and Healthcare Utilization
  212. Escitalopram Treatment of Generalized Anxiety Disorder in Older Adults—Reply
  213. Patient Participation and Physical Activity During Rehabilitation and Future Functional Outcomes in Patients After Hip Fracture
  214. Aripiprazole Prescribing Patterns and Side Effects in Elderly Psychiatric Inpatients
  215. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression
  216. Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression
  217. Escitalopram for Older Adults With Generalized Anxiety Disorder
  218. The utility of the Generalized Anxiety Disorder Severity Scale (GADSS) with older adults in primary care
  219. Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture
  220. Generalized Anxiety Disorder Severity Scale Validation in Older Adults
  221. Do Clinical Rehabilitation Education Programs Really Improve Stroke-Related Knowledge?
  222. Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late‐life anxiety disorders
  223. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder
  224. Rescue Pharmacotherapy With Duloxetine for Selective Serotonin Reuptake Inhibitor Nonresponders in Late-Life Depression
  225. An Open-Label Pilot Study of Acetylcholinesterase Inhibitors to Promote Functional Recovery in Elderly Cognitively Impaired Stroke Patients
  226. Residual symptoms and recurrence during maintenance treatment of late-life depression
  227. Biomarkers in Geriatric Psychiatry
  228. Stroke-Related Knowledge and Health Behaviors Among Poststroke Patients in Inpatient Rehabilitation
  229. Maintenance Treatment for Old‐Age Depression Preserves Health‐Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy
  230. Depressive symptoms in late life: associations with apathy, resilience and disability vary between young‐old and old‐old
  231. Preventing Depression in Medical Illness
  232. Cognitive Impairment in Late-Life Generalized Anxiety Disorder
  233. Recovery From Major Depression in Older Adults Receiving Augmentation of Antidepressant Pharmacotherapy
  234. Predicting 6‐week treatment response to escitalopram pharmacotherapy in late‐life major depressive disorder
  235. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study
  236. Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients?
  237. Onset of Depression in Elderly Persons After Hip Fracture: Implications for Prevention and Early Intervention of Late‐Life Depression
  238. Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life
  239. The Relationship Between Pain and Mental Flexibility in Older Adult Pain Clinic Patients
  240. Influence of Rehabilitation Site on Hip Fracture Recovery in Community-Dwelling Subjects at 6-Month Follow-Up
  241. Maintenance Treatment of Major Depression in Old Age
  242. Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment
  243. Evidence-Based Treatment of Geriatric Anxiety Disorders
  244. Predictors of Adequacy of Depression Management in the Primary Care Setting
  245. Dr. Lenze and Colleagues Reply
  246. Conclusions Inconsistent With Results With Citalopram
  247. Somatic symptoms of depression in elderly patients with medical comorbidities
  248. Comorbid anxiety disorder in late life depression: association with memory decline over four years
  249. Somatic Symptoms in Late-Life Anxiety: Treatment Issues
  250. Association of the Serotonin Transporter Gene-Linked Polymorphic Region (5-HTTLPR) Genotype With Depression in Elderly Persons After Hip Fracture
  251. The Course of Functional Decline in Older People with Persistently Elevated Depressive Symptoms: Longitudinal Findings from the Cardiovascular Health Study
  252. Effect of rehabilitation site on functional recovery after hip fracture
  253. Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial
  254. Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder
  255. Significance of poor patient participation in physical and occupational therapy for functional outcome and length of stay
  256. Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture
  257. The Pittsburgh Rehabilitation Participation Scale: reliability and validity of a clinician-rated measure of participation in acute rehabilitation
  258. Time Course of Response to Antidepressants in Late-Life Major Depression
  259. Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety
  260. Good treatment outcomes in late-life depression with comorbid anxiety
  261. Treatment Considerations for Anxiety in the Elderly
  262. Poster 74
  263. Comorbidity of depression and anxiety in the elderly
  264. Anxiety Disorders in Late Life: An Evolving Picture
  265. Risk Factors for Falls During Treatment of Late-Life Depression
  266. Clinically Relevant Behaviors in Elderly Hip Fracture Inpatients
  267. Effect of Cerebrovascular Risk Factors on Depression Treatment Outcome in Later Life
  268. Combined Pharmacotherapy and Psychotherapy as Maintenance Treatment for Late-Life Depression: Effects on Social Adjustment
  269. Anxiety Symptoms in Elderly Patients with Depression
  270. Subjective health measures and acute treatment outcomes in geriatric depression
  271. The Association of Late-Life Depression and Anxiety With Physical Disability: A Review of the Literature and Prospectus for Future Research
  272. Comorbidity of depression and anxiety disorders in later life
  273. Comorbid Anxiety Disorders in Depressed Elderly Patients
  274. White Matter Hyperintensities and Gray Matter Lesions in Physically Healthy Depressed Subjects
  275. Psychiatric Symptoms Endorsed by Somatization Disorder Patients in a Psychiatric Clinic
  276. Reactivation of Latent Herpes Simplex Virus by Excimer Laser Photokeratectomy